الفهرس | Only 14 pages are availabe for public view |
Abstract Solubility in the physiological fluids is one of the most important properties of a drug candidate. Poor aqueous solubility could affect drug absorption, bioavailability and ultimately pharmacological activity. Therefore, investigating different approaches to enhance solubility of poorly soluble drugs has been an essential element of pharmaceutical researches for decades. The need for such approaches has increased since the development of combinatorial chemistry and high throughput screening in the process of drug discovery. These techniques have resulted in large numbers of poorly soluble drug candidates. The problem of poor solubility has therefore become common in the pharmaceutical industry with percent of poorly water soluble compounds in development pipelines reaching as high as 70 to 90% depending on the therapeutic area. The pattern of this issue is now shifting to a point where some of the new drug candidates have both poor aqueous and organic solubilities, thus adding more challenges to formulation development. Piroxicam is a poorly soluble nonsteroidal anti-inflammatory drug used as an analgesic, antipyretic, and an anti-inflammatory medication. Administration of non-modified forms of the drug results in erratic absorption and low bioavailability. It was therefore chosen as a model drug in the current study. The aim of this study was to employ some of the solubility enhancement techniques to formulate the drug into oral dosage forms containing solubilized forms of it, while exploring the effect of some formulation variables on the resulting dosage forms |